Skip to content

How to treat peri-implantitis?

Clinical and microbiological evaluation of implant surface decontamination using 35% phosphoric etching gel during surgical treatment of peri-implantitis – a randomized clinical pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21821
Enrollment
27
Registered
2015-06-02
Start date
2013-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implantitis

Interventions

Peri-implant lesions were treated with resective surgical treatment consisting of apically repositioned flap, bone recontouring and surface debridement and decontamination. After mechanically cleaning

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria were: •≥ 18 years of age; •at least one endosseous implant with clinical and radiographical signs of peri-implantitis; •implants were in function for at least two years; •capable of understanding and providing informed consent.

Exclusion criteria

Exclusion criteria: •Contraindications for the surgical procedures; •A history of local radiotherapy to the head and neck region; •Pregnancy and lactation; •Insuline-dependent diabetes; •Systemic use of antibiotics during the last 3 months; •Long-term use of anti-inflammatory drugs; •Incapability of performing basal oral hygiene measures as a result of physical or mental disorders; •Uncontrolled periodontitis (PPD > 5mm); •Implants placed in skin grafted areas; •Implants with bone loss due to other reasons than bacterial infection (e.g. loose screw, inadequate positioning of the implant); •Implants with bone loss exceeding 2/3 of the length of the implant or implants with bone loss beyond the transverse openings in hollow implants; •Implant mobility; •Implants at which no position can be identified where proper probing measurements can be performed; •Previous surgical treatment of the peri-implantitis lesions.

Design outcomes

Primary

MeasureTime frame
Percentage of sites with bleeding on probing (% sites BoP) was used as primary clinical outcome variable

Secondary

MeasureTime frame
Secondary clinical outcome variables were presence of plaque (% sites plaque), suppuration on probing (% sites SoP), mean PPD and radio-graphical marginal bone loss at baseline. Next to this microbiolical parameters were recorded.

Contacts

Public ContactG.M. Raghoebar

University Medical Center Groningen (UMCG) Department of Oral Sugery P.O. Box 30001

g.m.raghoebar@kchir.umcg.nl+31(0)50 3613186

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)